الصفحة الرئيسية>>Signaling Pathways>> Others>>UKI-1 (UKI-1C)

UKI-1 (UKI-1C) (Synonyms: UKI-1C)

رقم الكتالوجGC32119

UKI-1 (UKI-1C) (UKI-1 (UKI-1C) C) هو مثبط فعال للبلازمينوجين من نوع urokinase (uPA) مع Ki من 0.41 μ ؛ M. UKI-1 (UKI-1C) هو أيضًا من مثبطات الأنزيم البروتيني السيرين منخفض الوزن الجزيئي. UKI-1 (UKI-1C) هو عامل فعال مضاد للقسط ويثبط القدرة الغازية للخلايا السرطانية.

Products are for research use only. Not for human use. We do not sell to patients.

UKI-1 (UKI-1C) التركيب الكيميائي

Cas No.: 220355-63-5

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
435٫00
متوفر
1mg
138٫00
متوفر
5mg
321٫00
متوفر
10mg
459٫00
متوفر
50mg
1379٫00
متوفر
100mg
1930٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

UKI-1 is a novel synthetic inhibitor of the urokinase-type plasminogen activator system. It can also inhibits the invasive capacity of carcinoma cells. (Ki=0.41 μM)In vitro : A decrease of tumor cell invasion by up to 50% was achieved in both models with the SCCHN line FaDu and the cervical carcinoma line HeLa after treatment with UK1.

[1]. Ertongur S et al. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer. 2004 Jul 20;110(6):815-24. [2]. Ewa Zeslawska et al. Crystals of the urokinase type plasminogen activator variant βc-uPA in complex with small molecule inhibitors open the way towards structure-based drug design. J Mol Biol. 2000 Aug 11;301(2):465-75.

مراجعات

Review for UKI-1 (UKI-1C)

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for UKI-1 (UKI-1C)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.